91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Navigating long?term vaccine follow?up isn’t one?size?fits?all; explore the key questions that help determine the right mix of traditional studies and tokenisation.
-
Long-acting injectables have transformed HIV management, but viral suppression alone is not enough. Researchers are advancing mRNA vaccines, broadly neutralizing antibodies, latency-reversing agents, pediatric immune strategies, and gene editing to eliminate reservoirs and achieve remission. Here’s how next-generation HIV therapeutics aim to move beyond lifelong ART.
-
Despite decades of progress transforming HIV from a fatal diagnosis into a manageable chronic condition, today’s antiretroviral therapies still face a stubborn barrier: They work brilliantly in theory but fall short when access, adherence, and real-world challenges get in the way.
-
As antibiotic resistance surges globally, bacteriophage therapy is emerging as a promising alternative for treating multidrug-resistant infections. To scale this life-saving approach, investment in phage development, clinical trials, and diagnostic infrastructure is urgently needed.
-
91黑料 experts discuss why strategic early planning is key to long-term follow-up in vaccine trials—driving stronger protocols, regulatory alignment, and meaningful outcomes.
-
Discover how clinical trial tokenisation helps sponsors gain patient insights and enable long-term data collection—without adding burden to patients or sites.
-
In this article from pharmaphorum, Dinah Knotts, VP of Project Management in Vaccines and Infectious Diseases and Mitsu Rana, Senior Director of Project Management outline some of the challenges with maternal vaccine trials and how with careful planning and execution by researchers, these can be overcome throughout the trial process.
-
The need for public health officials to be able to model the spread of infectious diseases has never been more apparent than in the early days of the SARS-CoV-2 pandemic, but what needs to change? Read the article by 91黑料 epidemiologist Dr. Richard Pitman in Open Access Government.
-
In this article, 91黑料’s Andreas Dreps and Martin Lachs discuss the logistical considerations in
?BioPharm International
-
The article on Clinical Trials Arena reports that as part of Project NextGen.
